PURPOSE: Data in the literature suggest that for painful bone metastases a single dose is as effective as fractionated radiotherapy. In the present multicentre prospective trial, the effects of 8 Gy x1 and 5 Gy x4 were compared. PATIENTS AND METHODS: A total of 241 patients were randomized to 8 Gy (122 patients) or 20 Gy (119 patients). The primary tumour was in the breast in 39% of patients, in the prostate in 34% of patients, in the lung in 13% of patients and in other locations in 14% of patients. Outcome measures were pain relief as measured by VAS and in half of the patients also by a five-point categorical pain scale, global quality of life (QoL) and analgesic consumption. Evaluation was performed before and 4, 8, 12 and 20 weeks after treatment. RESULTS: A total of 239 patients were evaluable for response. The two groups did not differ with respect to age, sex, primary tumour, metastasis localization, analgesic consumption (type and dose), performance status, prior systemic treatment, degree of pain and QoL. The treatment was completed as planned in 98% of patients. The degree of pain relief did not differ between the two treatment groups. At 4 weeks the difference in pain relief was 6% (95% CI 7, 20%) and at 8 weeks the difference was 13% (95% CI 3, 28%). Neither was there any significant difference in the duration of pain relief, the number of new painful sites and the need for reirradiation and toxicity was minor. CONCLUSION: The present randomized study showed that a single fraction of 8 Gy was as effective as 5 Gy x4 in relieving pain from bone metastasis.
RCT Entities:
PURPOSE: Data in the literature suggest that for painful bone metastases a single dose is as effective as fractionated radiotherapy. In the present multicentre prospective trial, the effects of 8 Gy x1 and 5 Gy x4 were compared. PATIENTS AND METHODS: A total of 241 patients were randomized to 8 Gy (122 patients) or 20 Gy (119 patients). The primary tumour was in the breast in 39% of patients, in the prostate in 34% of patients, in the lung in 13% of patients and in other locations in 14% of patients. Outcome measures were pain relief as measured by VAS and in half of the patients also by a five-point categorical pain scale, global quality of life (QoL) and analgesic consumption. Evaluation was performed before and 4, 8, 12 and 20 weeks after treatment. RESULTS: A total of 239 patients were evaluable for response. The two groups did not differ with respect to age, sex, primary tumour, metastasis localization, analgesic consumption (type and dose), performance status, prior systemic treatment, degree of pain and QoL. The treatment was completed as planned in 98% of patients. The degree of pain relief did not differ between the two treatment groups. At 4 weeks the difference in pain relief was 6% (95% CI 7, 20%) and at 8 weeks the difference was 13% (95% CI 3, 28%). Neither was there any significant difference in the duration of pain relief, the number of new painful sites and the need for reirradiation and toxicity was minor. CONCLUSION: The present randomized study showed that a single fraction of 8 Gy was as effective as 5 Gy x4 in relieving pain from bone metastasis.
Authors: Tong Liu; Svetlana Romanova; Shuo Wang; Megan A Hyun; Chi Zhang; Samuel M Cohen; Rakesh K Singh; Tatiana K Bronich Journal: Mol Pharm Date: 2019-06-14 Impact factor: 4.939
Authors: Yoonsun Chung; Woong Sub Koom; Yong Chan Ahn; Hee-Chul Park; Hak Jae Kim; Sang Min Yoon; Sangjin Shin; Yoon Jae Lee Journal: J Cancer Res Clin Oncol Date: 2013-10-10 Impact factor: 4.553
Authors: Anne M Walling; Phillip J Beron; Tania Kaprealian; Patrick A Kupelian; Neil S Wenger; Susan A McCloskey; Christopher R King; Michael Steinberg Journal: J Palliat Med Date: 2017-02-23 Impact factor: 2.947
Authors: A Gabriella Wernicke; Albert Sabbas; Fridon Kulidzhanov; Michael Shamis; Yevgeniya Golster; Ruben Niesvizky; Joseph Lane Journal: HSS J Date: 2011-12-17